Erol ÇAKMAK, Bülent SARAÇ, Hilmi ATASEVEN, Cumali ÇELİK, Özlem YÖNEM, Mesut PARLAK, İhsan BAĞCİVAN

Comparative Relaxant Effects of Ataciguat and Zaprinast on Sheep Sphincter of Oddi

Background: Relaxing the sphincter of Oddi (SO) is an important process during endoscopic retrograde cholangio-pancreatography (ERCP) procedures. This issue suggests that the easier the sphincterotomy and cannulation, the more post-ERCP complications decrease.Aims: To compare the relaxant effects of ataciguat (a novel soluble guanylyl cyclase activator) and zaprinast (an inhibi-tor of phosphodiesterase 5) on sheep SO in vitro, thus test-ing whether they can be used during ERCP. Study Design: Animal experimentation.Methods: Sheep SO rings were placed in tissue baths and their isometric tension to ataciguat and zaprinast were test-ed. We also tested their isometric tension against ataciguat in the presence of 1H-(1,2,4) oxadiazole (4,3-a) quinoxalin-1-one (ODQ) which is a soluble guanylyl cyclase inhibitor.Results: Ataciguat and zaprinast both triggered concen-tration addicted relaxation on sheep SO rings (p=0.0018, p=0.0025 respectively) but the relaxation of the ataciguat was significantly greater than that of zaprinast at all concen-trations (p=0.0024). It was observed that decreased relax-ation responses were initiated by ataciguat in the presence of ODQ (p=0.0012). Conclusion: Ataciguat and zaprinast both have relaxing effects on sphincter of Oddi, although that of zaprinast is lower. We believe that ataciguat and zaprinast can be used in ERCP procedures in order to relax the sphincter of Oddi and thus can be used locally in order to decrease complications.Keywords: Ataciguat, Oddi's sphincter, zaprinas

PDF

___

Bosch A, Peña LR. The sphincter of oddi. Dig Dis Sci 2007;52:1211-8. [Crossref]
Woods CM, Mawe GM, Toouli J, Saccone GT. The sphincter of Oddi: understanding its control and function. Neurogastroen- terol Motil 2005;1:31-40. [Crossref]
Wells DG, Talmage EK, Mawe GM. Immunohistochemical identification of neurons in ganglia of the guinea pig sphincter of Oddi. J Comp Neurol 1995;352:106-16. [Crossref]
Mourelle M, Guarner F, Moncada S, Malagelada JR. The ar- ginine/nitric oxide pathway modulates sphincter of Oddi mo- tor activity in guinea pigs and rabbits. Gastroenterology 1993;105:1299-305. [Crossref]
Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiol- ogy, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
Sarac B, Durmus N, Bagcivan I, Altun A, Turan M, Sencan M. Investigation of relaxant effects of new agents affecting nitric oxide/cyclic guanosine monophosphate pathway on sheep oddi sphincter. Pancreas 2010;39:875-8. [Crossref]
Denninger JW, Marletta MA. Guanylate cyclase and the NO/ cGMP signaling pathway. Biochim Biophys Acta 1999;1411:334- 50. [Crossref]
Cosyns SM, Huyghe L, Thoonen R, Stasch JP, Brouckaert P, Lefebvre RA. Influence of cinaciguat on gastrointestinal motil- ity in apo-sGC mice. Neurogastroenterol Motil 2014;26:1573- 85. [Crossref]
Choi SH, Choi DH, Song KS, Shin KH, Chun BG. Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neu- rosci Res 2002;67:411-21. [Crossref]
Taniguchi Y, Tonai-Kachi H, Shinjo K. Zaprinast, a well-known cy- clic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 2006;580:5003-8. [Crossref]
Ballester C, Sarriá B, García-Granero E, Morcillo EJ, Lledó S, Cortijo J. Relaxation of the isolated human internal anal sphinc- ter by sildenafil. Br J Surg 2007;94:894-902. [Crossref]
Tsai BM, Wang M, Pitcher JM, Kher A, Crisostomo P, Meldrum DR. Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. Shock 2005;24:417- 20. [Crossref]
Jones OM, Brading AF, McC Mortensen NJ. Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro. Dis Colon Rectum 2002;45:530-6. [Crossref]
Williams SJ, Parsons ME. Nitric oxide, an enteric nonadrener- gic-noncholinergic relaxant transmitter: evidence using phos- phodiesterase V and nitric oxide synthase inhibition. Br J Phar- macol 1995;116:1789-96. [Crossref]
Huang LY, Liu YX, Wu CR. Application ofendoscopic retro- grade cholangiopancreatography in biliarypancreatic diseases. Chinese Med J 2009;122:2967-72.
Shah V, Lyford G, Gores G, Farrugia G. Nitric oxide in gastroin- testinal health and disease. Gastroenterology 2004;126:903-13. [Crossref]
Rochester JS, Jaffe DL. Minimizing complications in endoscop- ic retrograde cholangio pancreatography and sphincterotomy. Gastrointest Endosc Clin N Am 2007;17:105-27. [Crossref]
Potter LR. Guanylyl cyclase structure, function and regulation. Cell Signal 2011;23:1921-6. [Crossref]
Buechler WA, Nakane M, Murad F. Expression of soluble gua- nylate cyclase activity requires both enzyme subunits. Biochem Biophys Res Commun 1991;174:351-7. [Crossref]
Bagcivan I, Kaya T, Turan M, Karadas B, Sarac B, Duman M. Comparative relaxant effects of YC-1 and DEA/NO on the sheep sphincter of Oddi. Pancreatology 2006;6:215-9. [Crossref]
Murray JA, Du C, Ledlow A, Manternach PL, Conklin JL. Guanylate cyclase inhibitors: effect on tone, relaxation, and cGMP content of lower esophageal sphincter. Am J Physiol 1992;263:97-101.
Friebe A, Mergia E, Dangel O, Lange A, Koesling D. Fatal gas- trointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc Natl Acad Sci U S A 2007;104:7699-704. [Crossref]
Schäfer A, Fraccarollo D, Werner L, Bauersachs J. Guanylyl cy- clase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res 2010;62:432- 8. [Crossref]
Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674-82. [Crossref]
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunc- tion: Sildenafil Study Group. N Engl J Med 1998;338:1397-404. [Crossref]
De Witt BJ, Marrone JR, Kadowitz PJ. Comparison of responses to siguazodan, rolipram, and zaprinast in the feline pulmonary vascular bed. Eur J Pharmacol 2000;406:233-8. [Crossref]
Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hyper- tension. N Engl J Med 2005;353:2148-57. [Crossref]
Eherer AJ, Schwetz I, Hammer HF, Petnehazy T, Scheidl SJ, Weber K, et al. Effect of sildenafil on oesophageal motor func- tion in healthy subjects and patients with oesophageal motor dis- orders. Gut 2002;50:758-64. [Crossref]
Cheon YK, Cho YD, Moon JH, Im HH, Jung Y, Lee JS, et al. Effects of vardenafil, a phosphodiesterase type-5 inhibi- tor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009;69:1111-6. [Crossref]
Barnette MS, Barone FC, Fowler PJ, Grous M, Price WJ, Orms- bee HS. Human lower oesophageal sphincter relaxation is as- sociated with raised cyclic nucleotide content. Gut 1991;32:4-9. [Crossref]